Date closed: 7/17/2017
Value: C$342 million
On July 17, 2017, Norgine B.V. (Norgine) completed the acquisition of Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) (Merus) pursuant to which Norgine acquired all of the issued and outstanding common shares of Merus and shareholders of Merus received cash consideration equal to C$1.65 per Share for a total consideration of approximately C$342 million.
Norgine, headquartered in Amsterdam, The Netherland, is a leading European specialist pharmaceutical with a direct commercial presence in all major European markets.
Merus, headquartered in Toronto, Ontario, is a specialty pharmaceutical company.
BLG is acting for Clarus Securities Inc., as financial advisor to Merus, with a team led by Andrew Powers.
